A double-blind comparison of clovoxamine and amitriptyline in the treatment of depressed outpatients.
Forty-two outpatients with major depression were treated in a 4-week double-blind parallel-group comparison of the new antidepressant clovoxamine--a member of oximethers of aralkylketones--with amitriptyline. The two drugs were comparable in efficacy, although because of the small sample size a moderate clinical difference between treatments may not have been detected. The magnitude of unwanted effects also was comparable, but clovoxamine produced fewer "anticholinergic" effects; this was determined by patient complaints of typical anticholinergic symptoms, by decreased salivary flow, and by a new signal detection memory test.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000639:Amitriptyline / Q000009:adverse effects / Q000627:therapeutic use*; D000928:Antidepressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008568:Memory / Q000187:drug effects; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D010091:Oximes / Q000009:adverse effects / Q000627:therapeutic use*; D010276:Parasympatholytics / Q000627:therapeutic use; D010349:Patient Compliance; D011569:Psychiatric Status Rating Scales; D012472:Salivation / Q000187:drug effects
D000928:Antidepressive Agents; D010091:Oximes; D010276:Parasympatholytics; D000639:Amitriptyline; C020724:clovoxamine